biostudies-literatureNappi LNCI NIH HHS3090-3098https://www.ebi.ac.uk/biostudies/studies/S-EPMC7351323biostudies-literatureUnknown37(33)<h4>Purpose</h4>Our objective was to evaluate operating characteristics, particularly specificity and positive predictive value (PPV), by mapping plasma miR371 expression to actual clinical events in patients with a history of germ cell tumor.<h4>Patients and methods</h4>One hundred eleven male patients with a history of or newly diagnosed germ cell tumors were evaluable. Biospecimens obtained before confirmed clinical events were analyzed for miR371 expression with blinding of providers and laboratory personnel to analytic results or clinical status, respectively. Cases (patients with clinically confirmed active germ cell malignancy [aGCM]) and controls (patients with no clinically confirmed aGCM) were assigned over the course of the management. Patients were assigned risk status (high, lJournal of clinical oncology : official journal of the American Society of Clinical OncologyDeveloping a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum.PMC7351323U10 CA180888Lum AWyatt AWGleave MNappi LEigl BJMaughan BLBlack PCMartin CChi KThi MHuntsman DKhalaf DBell RLeao RRNKollmannsberger CDaneshmand SSo AHamilton RJLavoie JMNichols CO'Neil BfalseDeveloping a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum.<h4>Purpose</h4>Our objective was to evaluate operating characteristics, particularly specificity and positive predictive value (PPV), by mapping plasma miR371 expression to actual clinical events in patients with a history of germ cell tumor.<h4>Patients and methods</h4>One hundred eleven male patients with a history of or newly diagnosed germ cell tumors were evaluable. Biospecimens obtained before confirmed clinical events were analyzed for miR371 expression with blinding of providers and laboratory personnel to analytic results or clinical status, respectively. Cases (patients with clinically confirmed active germ cell malignancy [aGCM]) and controls (patients with no clinically confirmed aGCM) were assigned over the course of the management. Patients were assigned risk status (high, l2019-01-01T00:00:00Z2019 Nov2025-06-01T02:35:07.214Z2020-11-19T13:29:06ZS-EPMC73513233155369210.1200/jco.18.0205710.1200/JCO.18.02057